Literature DB >> 8928761

Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function.

M M Byrne1, J Sturis, R J Sobel, K S Polonsky.   

Abstract

Studies were performed in subjects with no known family history of diabetes, normoglycemic subjects who have first-degree relatives with non-insulin-dependent diabetes mellitus (NIDDM), and subjects with nondiagnostic oral glucose tolerance tests (NDX) or impaired glucose tolerance (IGT). Insulin sensitivity index (SI) was similar in all four groups. However, a number of defects in insulin secretion were seen in the NDX and IGT groups, including reduced first-phase insulin secretory responses in intravenous glucose in relation to the degree of insulin resistance, and reduced normalized spectral power of insulin secretion during oscillatory glucose infusion. The latter finding demonstrates a decreased ability of the beta-cell to detect and respond to the successive increases and decreases in glucose and therefore to be entrained by the exogenous glucose infusion. The ability of a low-dose glucose infusion to prime the insulin secretory response to a subsequent glucose stimulus was normal in subjects with IGT but reduced or absent in subjects with overt NIDDM. These studies demonstrate that a number of alterations in beta-cell function are detectable in nondiabetic first-degree relatives of subjects with NIDDM with mild elevations in the 2-h postchallenge glucose level, and these abnormalities antedate the onset of overt hyperglycemia and clinical diabetes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8928761     DOI: 10.1152/ajpendo.1996.270.4.E572

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.

Authors:  M K Cavaghan; D A Ehrmann; K S Polonsky
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

Review 3.  Dynamics of insulin secretion and the clinical implications for obesity and diabetes.

Authors:  Susumu Seino; Tadao Shibasaki; Kohtaro Minami
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

4.  Role of the SIK2-p35-PJA2 complex in pancreatic β-cell functional compensation.

Authors:  Jun-Ichi Sakamaki; Accalia Fu; Courtney Reeks; Stephen Baird; Chantal Depatie; Mufida Al Azzabi; Nabeel Bardeesy; Anne-Claude Gingras; Siu-Pok Yee; Robert A Screaton
Journal:  Nat Cell Biol       Date:  2014-03       Impact factor: 28.824

5.  Effects of intensive insulin therapy upon pancreatic β cell function in patients newly diagnosed with type II diabetes.

Authors:  Defeng Wang; Li Sun; Guangyao Song; Shuchun Chen
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.

Authors:  M K Cavaghan; D A Ehrmann; M M Byrne; K S Polonsky
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

7.  Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.

Authors:  Kelvin Lingjet Tran; Young In Park; Shalin Pandya; Navin John Muliyil; Brandon David Jensen; Kovin Huynh; Quang T Nguyen
Journal:  Am Health Drug Benefits       Date:  2017-06

8.  Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulin.

Authors:  Laura E Trask; Sushela S Chaidarun; David Platt; Christopher G Parkin
Journal:  J Diabetes Sci Technol       Date:  2014-06-12

9.  Different pathophysiology of impaired glucose tolerance in first-degree relatives of individuals with type 2 diabetes mellitus.

Authors:  Peter Emerson; Timon W Van Haeften; Walkyria Pimenta; Elena Plummer; Hans J Woerle; Asimina Mitrakou; Ervin Szoke; John Gerich; Christian Meyer
Journal:  Metabolism       Date:  2009-05       Impact factor: 8.694

Review 10.  Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus.

Authors:  Michael Bergman
Journal:  Endocrine       Date:  2012-11-07       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.